PURPOSE: Vancomycin-Resistant Enterococci (VRE) are important causes of Intensive Care Unit (ICU) infections. Our goal was to identify the prevalence and risk factors for VRE colonization upon ICU admission and during ICU stay, as well as, their impact in enterococcal infection including vancomycin-susceptible cases (VSE). METHODS: A prospective study regarding patients admitted in ICU (n = 497) was conducted during a 24-month period. Rectal swabs were collected upon admission and during hospitalization and inoculated onto selective medium. Enterococci were phenotypically characterized. van genes were investigated by PCR and clones were identified by Pulsed-Field Gel Electrophoresis and Multilocus Sequence Typing. Epidemiologic data were collected from the ICU database. RESULTS: Risk factors for VRE carriage upon ICU admission (71/497) were: duration of previous hospitalization, glycopeptide administration, chronic heart failure, malignancy, insulin-dependent diabetes mellitus, and previous enterococcal infection (VRE and/or VSE). Risk factors for VRE colonization during ICU stay (36/250) were: quinolone administration, chronic obstructive pulmonary disease, chronic renal failure, and number of VRE-positive patients in nearby beds. Risk factors for enterococcal infection during ICU stay (15/284), including VRE and VSE cases, were: administration of third- or fourth-generation cephalosporins, cortisone use before ICU admission and VRE colonization, whereas, enteral nutrition was a protective factor. CONCLUSIONS: Previous VRE colonization and antibiotic usage are essential parameters for enterococcal infection (by VRE or VSE) during ICU stay. Previous enterococcal infection, co-morbidities and antibiotic usage are associated with VRE colonization upon ICU admission, whereas, patient to patient transmission, co-morbidities and antibiotic usage constitute risk factors for VRE colonization during ICU hospitalization.
PURPOSE:Vancomycin-Resistant Enterococci (VRE) are important causes of Intensive Care Unit (ICU) infections. Our goal was to identify the prevalence and risk factors for VRE colonization upon ICU admission and during ICU stay, as well as, their impact in enterococcal infection including vancomycin-susceptible cases (VSE). METHODS: A prospective study regarding patients admitted in ICU (n = 497) was conducted during a 24-month period. Rectal swabs were collected upon admission and during hospitalization and inoculated onto selective medium. Enterococci were phenotypically characterized. van genes were investigated by PCR and clones were identified by Pulsed-Field Gel Electrophoresis and Multilocus Sequence Typing. Epidemiologic data were collected from the ICU database. RESULTS: Risk factors for VRE carriage upon ICU admission (71/497) were: duration of previous hospitalization, glycopeptide administration, chronic heart failure, malignancy, insulin-dependent diabetes mellitus, and previous enterococcal infection (VRE and/or VSE). Risk factors for VRE colonization during ICU stay (36/250) were: quinolone administration, chronic obstructive pulmonary disease, chronic renal failure, and number of VRE-positive patients in nearby beds. Risk factors for enterococcal infection during ICU stay (15/284), including VRE and VSE cases, were: administration of third- or fourth-generation cephalosporins, cortisone use before ICU admission and VRE colonization, whereas, enteral nutrition was a protective factor. CONCLUSIONS: Previous VRE colonization and antibiotic usage are essential parameters for enterococcal infection (by VRE or VSE) during ICU stay. Previous enterococcal infection, co-morbidities and antibiotic usage are associated with VRE colonization upon ICU admission, whereas, patient to patient transmission, co-morbidities and antibiotic usage constitute risk factors for VRE colonization during ICU hospitalization.
Authors: B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild Journal: Infection Date: 2012-06-05 Impact factor: 3.553
Authors: H P Endtz; N Van Den Braak; A Van Belkum; W H Goessens; D Kreft; A B Stroebel; H A Verbrugh Journal: J Clin Microbiol Date: 1998-02 Impact factor: 5.948
Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948
Authors: Joon Young Song; Hee Jin Cheong; Yu Mi Jo; Won Suk Choi; Ji Yun Noh; Jung Yeon Heo; Woo Joo Kim Journal: Am J Infect Control Date: 2009-02-01 Impact factor: 2.918
Authors: Kevin Heinze; Mohammed Kabeto; Emily Toth Martin; Marco Cassone; Liam Hicks; Lona Mody Journal: Am J Infect Control Date: 2018-11-28 Impact factor: 2.918
Authors: M Papadimitriou-Olivgeris; I Spiliopoulou; M Christofidou; D Logothetis; P Manolopoulou; V Dodou; F Fligou; M Marangos; E D Anastassiou Journal: Eur J Clin Microbiol Infect Dis Date: 2015-07-15 Impact factor: 3.267
Authors: Liana Signorini; Giovanni Moioli; Stefano Calza; Evelyn Van Hauwermeiren; Silvia Lorenzotti; Giovanni Del Fabro; Giulia Renisi; Paola Lanza; Barbara Saccani; Giulia Zambolin; Nicola Latronico; Francesco Castelli; Sergio Cattaneo; John C Marshall; Alberto Matteelli; Simone Piva Journal: Crit Care Explor Date: 2021-06-11